State and federal legislative updates affecting dermatology practice in Connecticut, tracked and advocated for by the Society.
Active
CT SB 1022
Scope of Practice — Advanced Practice Providers in Dermatology
Legislation under review that would expand the scope of practice for advanced practice providers performing dermatologic procedures in Connecticut, including certain surgical and cosmetic treatments currently restricted to licensed physicians.
Status: Public Hearing — Joint Committee on Public HealthSession: 2025
Proposed legislation to reform step therapy protocols for biologic medications in dermatology, requiring insurers to honor existing treatment regimens and streamlining prior authorization for established dermatologic biologics.
Signed into law in 2024, this act extended telehealth reimbursement parity for dermatology services including teledermatology consultations and store-and-forward imaging through December 2026.
Status: Signed into Law — 2024Effective: January 1, 2025
Monitor
CT SB 892
Pharmacy Benefit Manager Transparency Act
Legislation requiring greater transparency from pharmacy benefit managers regarding formulary decisions and drug pricing, with potential impact on dermatologic biologic and specialty drug access for Connecticut patients.
Status: Referred to Commerce CommitteeSession: 2025
Active
CMS 2025
Physician Fee Schedule — Dermatology Impact
The 2025 CMS Physician Fee Schedule final rule includes reimbursement adjustments affecting dermatology procedure codes. The Society, in coordination with the AAD, is tracking implementation and advocating for equitable reimbursement.
New FDA draft guidance on interchangeability standards for topical biologics and biosimilars in dermatology, including dupilumab and IL-17 inhibitor biosimilars entering the market in 2025.
Status: Public Comment Period OpenSource: FDA.gov
Active
S. 2440
GOLD Card Act — Prior Authorization Reform
Federal legislation that would exempt physicians who meet quality benchmarks from prior authorization requirements under Medicare Advantage, with significant implications for dermatology practices nationwide.
Status: Senate Finance CommitteeSession: 119th Congress
Apr 2025
Connecticut
SB 1022 Public Hearing — Society Testimony Submitted
The Connecticut Society of Dermatology and Dermatologic Surgery submitted written testimony regarding scope-of-practice expansion for non-physician providers performing dermatologic surgical procedures, emphasizing patient safety standards.
Mar 2025
Federal
AAD Advocacy Day — Connecticut Delegation Participates
Connecticut dermatologists participated in the AAD's annual advocacy day in Washington, meeting with congressional delegations to discuss prior authorization reform, scope of practice, and Medicare reimbursement.
The 2025 CMS Physician Fee Schedule final rule went into effect January 1. Dermatology-specific adjustments include changes to E&M visit coding, Mohs surgery reimbursement, and phototherapy procedure valuations.
FDA Approves New IL-13 Inhibitor for Atopic Dermatitis
The FDA approved a new interleukin-13 inhibitor biologic for moderate-to-severe atopic dermatitis in adults, expanding the therapeutic options available to dermatologists.
Nov 2024
Connecticut
Telehealth Parity Extended Through 2026
CT PA 24-112 extended telehealth reimbursement parity for dermatology services including teledermatology and store-and-forward imaging consultations through December 31, 2026.
Physicians may use this form to raise legislative concerns, ask questions about pending legislation, or request advocacy on matters affecting their practice in Connecticut.
For time-sensitive matters, contact Debbie Osborn directly at (860) 567-3787. Messages submitted here are reviewed within two business days.
Your information is kept confidential and shared only with the CTDS legislative team.